Central India Chronicle

Ovarian Cancer Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

 Breaking News
  • No posts were found

Ovarian Cancer Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

November 16
21:50 2022
Ovarian Cancer Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments
Ovarian Cancer pipeline constitutes 100+ key companies continuously working towards developing 100+ Ovarian Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Ovarian Cancer Overview

Ovarian cancer is a disease that affects women and is a group of diseases that originates in the ovaries, or in the related areas of the fallopian tubes and the peritoneum. In this form of cancer, certain cells in the ovary become abnormal and multiply uncontrollably to form a tumor. The ovaries are the female reproductive organs in which egg cells are produced. In about 90 percent of cases, ovarian cancer occurs after age 40, and most cases occur after age 60.

 

Ovarian Cancer Pipeline Insight, 2022″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Ovarian Cancer Market.

 

The Ovarian Cancer Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the Ovarian Cancer Pipeline Report: 

  • Companies across the globe are diligently working toward developing novel Ovarian Cancer treatment therapies with a considerable amount of success over the years. Ovarian Cancer Key players such as – ImmunoGen, Daiichi Sankyo, Shattuck Labs, Inc., AstraZeneca, Allarity Therapeutics, Genmab, VBL Therapeutics, Merck, Aravive, and others, are developing therapies for the Ovarian Cancer treatment 
  • Ovarian Cancer Emerging therapies such as – IMGN151, DS-6000, SL-172154, Adavosertib, 2X-121, Tisotumab vedotin, VB-111, Pembrolizumab, AVB-500, and others are expected to have a significant impact on the Ovarian Cancer market in the coming years.   
  • In April 2021, Aravive initiated a global, randomized, double-blind, placebo-controlled adaptive trial (GOG-3059/ENGOT OV-66) is designed to evaluate efficacy and safety of AVB-500 at a dose of 15 mg/kg in combination with paclitaxel.

 

Ovarian Cancer Pipeline Therapeutics Assessment

  • Ovarian Cancer Assessment by Product Type
  • Ovarian Cancer By Stage and Product Type
  • Ovarian Cancer Assessment by Route of Administration
  • Ovarian Cancer By Stage and Route of Administration
  • Ovarian Cancer Assessment by Molecule Type
  • Ovarian Cancer by Stage and Molecule Type

 

DelveInsight’s Ovarian Cancer Report covers around 100+ products under different phases of clinical development like

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Emerging Ovarian Cancer Drugs Under Different Phases of Clinical Development Include:

  • IMGN151: ImmunoGen
  • DS-6000: Daiichi Sankyo
  • SL-172154: Shattuck Labs, Inc.
  • Adavosertib: AstraZeneca
  • 2X-121: Allarity Therapeutics
  • Tisotumab vedotin: Genmab
  • VB-111: VBL Therapeutics
  • Pembrolizumab: Merck
  • AVB-500: Aravive

 

Get a Free Sample PDF Report to know more about Ovarian Cancer Pipeline Assessment

 

Ovarian Cancer Pipeline Analysis:

The Ovarian Cancer pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the Ovarian Cancer treatment with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Ovarian Cancer Treatment.
  • Ovarian Cancer key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • Ovarian Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Ovarian Cancer market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further Ovarian Cancer product details are provided in the report. Download the Ovarian Cancer pipeline report to learn more about the emerging Ovarian Cancer therapies 

 

Ovarian Cancer Pipeline Market Drivers

  • Increase in incidences of ovarian cancer
  • Rising investment for the development of advanced technologies
  • Surge in government initiatives to promote research and awareness about the disease

 

Ovarian Cancer Pipeline Market Barriers

  • High cost associated with the Ovarian Cancer treatment
  • Lack of skilled professionals for early diagnosis of the disease
  • Stringent regulation in drug testing

 

Scope of Ovarian Cancer Pipeline Drug Insight    

  • Coverage: Global
  • Key Ovarian Cancer Companies: ImmunoGen, Daiichi Sankyo, Shattuck Labs, Inc., AstraZeneca, Allarity Therapeutics, Genmab, VBL Therapeutics, Merck, Aravive, and others
  • Key Ovarian Cancer Therapies: IMGN151, DS-6000, SL-172154, Adavosertib, 2X-121, Tisotumab vedotin, VB-111, Pembrolizumab, AVB-500, and others
  • Ovarian Cancer Therapeutic Assessment: Ovarian Cancer current marketed and Ovarian Cancer emerging therapies
  • Ovarian Cancer Market Dynamics: Ovarian Cancer market drivers and Ovarian Cancer market barriers 

 

Request for Sample PDF Report for Ovarian Cancer Pipeline Assessment and clinical trials

 

Table of Contents

1

Ovarian Cancer Report Introduction

2

Ovarian Cancer Executive Summary

3

Ovarian Cancer Overview

4

Ovarian Cancer- Analytical Perspective In-depth Commercial Assessment

5

Ovarian Cancer Pipeline Therapeutics

6

Ovarian Cancer Late Stage Products (Phase II/III)

7

Ovarian Cancer Mid Stage Products (Phase II)

8

Ovarian Cancer Early Stage Products (Phase I)

9

Ovarian Cancer Preclinical Stage Products

10

Ovarian Cancer Therapeutics Assessment

11

Ovarian Cancer Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

Ovarian Cancer Key Companies

14

Ovarian Cancer Key Products

15

Ovarian Cancer Unmet Needs

16 

Ovarian Cancer Market Drivers and Barriers

17

Ovarian Cancer Future Perspectives and Conclusion

18

Ovarian Cancer Analyst Views

19

Appendix

20

About DelveInsight

 

Download Sample PDF Report to know more about Ovarian Cancer drugs and therapies

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/

Related Articles